TD Asset Management’s Pliant Therapeutics PLRX Stock Holding History

TD Asset Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-78,034	Closed	-$1.03M	–	1257
2024 Q4	$1.03M	Hold	78,034	–	–	﹤0.01%	1105
2024 Q3	$883K	Sell	78,034 -34,214	-30%	-$428K	﹤0.01%	1211
2024 Q2	$1.21M	Hold	112,248	–	–	﹤0.01%	1129
2024 Q1	$1.67M	Hold	112,248	–	–	﹤0.01%	1064
2023 Q4	$2.03M	Hold	112,248	–	–	﹤0.01%	1003
2023 Q3	$1.95M	Buy	112,248 +56,124	+100%	+$973K	﹤0.01%	965
2023 Q2	$1.02M	Buy	56,124 +5,300	+10%	+$125K	﹤0.01%	1130
2023 Q1	$1.35M	Buy	50,824 +21,264	+72%	+$605K	﹤0.01%	1082
2022 Q4	$571K	Hold	29,560	–	–	﹤0.01%	1263
2022 Q3	$614K	Buy	+29,560	New	+$566K	﹤0.01%	1258
2021 Q3	–	Sell	-14,442	Closed	-$292K	–	1549
2021 Q2	$292K	Hold	14,442	–	–	﹤0.01%	1446
2021 Q1	$568K	Buy	+14,442	New	+$469K	﹤0.01%	1378

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

TD Asset Management's PLRX Position: Q1 2025 in Review

TD Asset Management sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 78,034 shares — an estimated $1.03M sold.

TD Asset Management first reported a position in PLRX in Q1 2021 and held it in 12 quarters. The position peaked at $2.03M in Q4 2023. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

TD Asset Management reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
TD Asset Management sold 78,034 Pliant Therapeutics shares in Q1 2025, an estimated $1.03M.
TD Asset Management first reported a position in Pliant Therapeutics in Q1 2021 and held it in 12 quarters.
TD Asset Management's Pliant Therapeutics position peaked at $2.03M in Q4 2023.
140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on TD Asset Management's 13F filing for Q1 2025, filed 7 May 2025.